259 related articles for article (PubMed ID: 21904802)
1. Evaluation of the potential of PET-MRI fusion for detection of liver metastases in patients with neuroendocrine tumours.
Schreiter NF; Nogami M; Steffen I; Pape UF; Hamm B; Brenner W; Röttgen R
Eur Radiol; 2012 Feb; 22(2):458-67. PubMed ID: 21904802
[TBL] [Abstract][Full Text] [Related]
2. Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours.
Kumar R; Sharma P; Garg P; Karunanithi S; Naswa N; Sharma R; Thulkar S; Lata S; Malhotra A
Eur Radiol; 2011 Nov; 21(11):2408-16. PubMed ID: 21750886
[TBL] [Abstract][Full Text] [Related]
3. Value of retrospective fusion of PET and MR images in detection of hepatic metastases: comparison with 18F-FDG PET/CT and Gd-EOB-DTPA-enhanced MRI.
Donati OF; Hany TF; Reiner CS; von Schulthess GK; Marincek B; Seifert B; Weishaupt D
J Nucl Med; 2010 May; 51(5):692-9. PubMed ID: 20395324
[TBL] [Abstract][Full Text] [Related]
4. Qualitative and quantitative image analysis of CT and MR imaging in patients with neuroendocrine liver metastases in comparison to (68)Ga-DOTATOC PET.
Flechsig P; Zechmann CM; Schreiweis J; Kratochwil C; Rath D; Schwartz LH; Schlemmer HP; Kauczor HU; Haberkorn U; Giesel FL
Eur J Radiol; 2015 Aug; 84(8):1593-1600. PubMed ID: 25999064
[TBL] [Abstract][Full Text] [Related]
5. Staging of neuroendocrine tumours: comparison of [⁶⁸Ga]DOTATOC multiphase PET/CT and whole-body MRI.
Schraml C; Schwenzer NF; Sperling O; Aschoff P; Lichy MP; Müller M; Brendle C; Werner MK; Claussen CD; Pfannenberg C
Cancer Imaging; 2013 Mar; 13(1):63-72. PubMed ID: 23466785
[TBL] [Abstract][Full Text] [Related]
6. Comparison of neuroendocrine tumor detection and characterization using DOTATOC-PET in correlation with contrast enhanced CT and delayed contrast enhanced MRI.
Giesel FL; Kratochwil C; Mehndiratta A; Wulfert S; Moltz JH; Zechmann CM; Kauczor HU; Haberkorn U; Ley S
Eur J Radiol; 2012 Oct; 81(10):2820-5. PubMed ID: 22236704
[TBL] [Abstract][Full Text] [Related]
7. Are contrast media required for (68)Ga-DOTATOC PET/CT in patients with neuroendocrine tumours of the abdomen?
Mayerhoefer ME; Schuetz M; Magnaldi S; Weber M; Trattnig S; Karanikas G
Eur Radiol; 2012 Apr; 22(4):938-46. PubMed ID: 22080251
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of
Sawicki LM; Deuschl C; Beiderwellen K; Ruhlmann V; Poeppel TD; Heusch P; Lahner H; Führer D; Bockisch A; Herrmann K; Forsting M; Antoch G; Umutlu L
Eur Radiol; 2017 Oct; 27(10):4091-4099. PubMed ID: 28439648
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic accuracy of dynamic gadoxetic-acid-enhanced MRI and PET/CT compared in patients with liver metastases from neuroendocrine neoplasms.
Armbruster M; Zech CJ; Sourbron S; Ceelen F; Auernhammer CJ; Rist C; Haug A; Singnurkar A; Reiser MF; Sommer WH
J Magn Reson Imaging; 2014 Aug; 40(2):457-66. PubMed ID: 24347148
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography.
Armbruster M; Sourbron S; Haug A; Zech CJ; Ingrisch M; Auernhammer CJ; Nikolaou K; Paprottka PM; Rist C; Reiser MF; Sommer WH
Invest Radiol; 2014 Jan; 49(1):7-14. PubMed ID: 24002080
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
Beiderwellen KJ; Poeppel TD; Hartung-Knemeyer V; Buchbender C; Kuehl H; Bockisch A; Lauenstein TC
Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
[TBL] [Abstract][Full Text] [Related]
12. Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours.
Schreiter NF; Brenner W; Nogami M; Buchert R; Huppertz A; Pape UF; Prasad V; Hamm B; Maurer MH
Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):72-82. PubMed ID: 21927931
[TBL] [Abstract][Full Text] [Related]
13. Comparison of diagnostic accuracy of (111)In-pentetreotide SPECT and (68)Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours.
Van Binnebeek S; Vanbilloen B; Baete K; Terwinghe C; Koole M; Mottaghy FM; Clement PM; Mortelmans L; Bogaerts K; Haustermans K; Nackaerts K; Van Cutsem E; Verslype C; Verbruggen A; Deroose CM
Eur Radiol; 2016 Mar; 26(3):900-9. PubMed ID: 26162577
[TBL] [Abstract][Full Text] [Related]
14. Clinical value of ⁶⁸Ga-DOTATATE-PET/CT compared to stand-alone contrast enhanced CT for the detection of extra-hepatic metastases in patients with neuroendocrine tumours (NET).
Albanus DR; Apitzsch J; Erdem Z; Erdem O; Verburg FA; Behrendt FF; Mottaghy FM; Heinzel A
Eur J Radiol; 2015 Oct; 84(10):1866-72. PubMed ID: 26152870
[TBL] [Abstract][Full Text] [Related]
15. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors.
Frilling A; Sotiropoulos GC; Radtke A; Malago M; Bockisch A; Kuehl H; Li J; Broelsch CE
Ann Surg; 2010 Nov; 252(5):850-6. PubMed ID: 21037441
[TBL] [Abstract][Full Text] [Related]
16. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.
Putzer D; Gabriel M; Henninger B; Kendler D; Uprimny C; Dobrozemsky G; Decristoforo C; Bale RJ; Jaschke W; Virgolini IJ
J Nucl Med; 2009 Aug; 50(8):1214-21. PubMed ID: 19617343
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor.
Hope TA; Pampaloni MH; Nakakura E; VanBrocklin H; Slater J; Jivan S; Aparici CM; Yee J; Bergsland E
Abdom Imaging; 2015 Aug; 40(6):1432-40. PubMed ID: 25820755
[TBL] [Abstract][Full Text] [Related]
18. Impact of Multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors.
Ruf J; Heuck F; Schiefer J; Denecke T; Elgeti F; Pascher A; Pavel M; Stelter L; Kropf S; Wiedenmann B; Amthauer H
Neuroendocrinology; 2010; 91(1):101-9. PubMed ID: 19996582
[TBL] [Abstract][Full Text] [Related]
19. Additional information gained by positron emission tomography with (68)Ga-DOTATOC for suspected unknown primary or recurrent neuroendocrine tumors.
Nakamoto Y; Sano K; Ishimori T; Ueda M; Temma T; Saji H; Togashi K
Ann Nucl Med; 2015 Jul; 29(6):512-8. PubMed ID: 25894056
[TBL] [Abstract][Full Text] [Related]
20. Gadoxetate disodium-enhanced magnetic resonance imaging versus contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of colorectal liver metastases.
Seo HJ; Kim MJ; Lee JD; Chung WS; Kim YE
Invest Radiol; 2011 Sep; 46(9):548-55. PubMed ID: 21577131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]